These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33009577)

  • 1. Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
    Genestie C; Auguste A; Al Battal M; Scoazec JY; Gouy S; Lacroix L; Morice P; Pautier P; Leary A; Devouassoux-Shisheboran M
    Virchows Arch; 2021 May; 478(5):885-891. PubMed ID: 33009577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis.
    Hada T; Miyamoto M; Ohtsuka Y; Suminokura J; Ito T; Kishimoto N; Nishitani S; Takada M; Imauji A; Tanabe R; Takano M
    Diagn Pathol; 2023 Apr; 18(1):49. PubMed ID: 37081552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
    Rodríguez IM; Prat J
    Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature.
    Hada T; Miyamoto M; Ishibashi H; Matsuura H; Sakamoto T; Kakimoto S; Iwahashi H; Tsuda H; Takano M
    J Ovarian Res; 2021 Feb; 14(1):33. PubMed ID: 33583413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
    Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
    Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
    Köbel M; Kang EY; Lee S; Terzic T; Karnezis AN; Ghatage P; Woo L; Lee CH; Meagher NS; Ramus SJ; Gorringe KL
    Histopathology; 2024 Jun; 84(7):1095-1110. PubMed ID: 38155475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis.
    Hada T; Miyamoto M; Ishibashi H; Matsuura H; Kakimoto S; Iwahashi H; Tsuda H; Takano M
    Diagn Pathol; 2022 Jan; 17(1):12. PubMed ID: 35057833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
    Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
    Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
    Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
    Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presentation and Prognosis of Primary Expansile and Infiltrative Mucinous Carcinomas of the Ovary.
    Huin M; Lorenzini J; Arbion F; Carcopino X; Touboul C; Dabi Y; Kerbage Y; Costaz H; Lecointre L; Lavoué V; Bolze PA; Huchon C; Bricou A; Canlorbe G; Mimoun C; Bendifallah S; Gauthier T; Body G; Ouldamer L;
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294441
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases.
    Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Siriaunkgul S
    Int J Gynecol Pathol; 2014 Mar; 33(2):176-85. PubMed ID: 24487473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucinous borderline ovarian tumors with BRAF
    Ohnishi K; Nakayama K; Ishikawa M; Ishibashi T; Yamashita H; Nakamura K; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Arch Gynecol Obstet; 2020 Aug; 302(2):487-495. PubMed ID: 32556513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
    Lee KR; Scully RE
    Am J Surg Pathol; 2000 Nov; 24(11):1447-64. PubMed ID: 11075847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucinous tumors of the ovary: a review.
    Hart WR
    Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with early stage mucinous ovarian carcinoma: a Dutch population-based cohort study comparing expansile and infiltrative subtypes.
    Algera MD; Van de Vijver KK; van Driel WJ; Slangen BFM; Lof FC; van der Aa M; Kruitwagen RFPM; Lok CAR
    Int J Gynecol Cancer; 2024 May; 34(5):722-729. PubMed ID: 38460968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic similarity between ovarian mucinous carcinoma with expansile invasion and ovarian mucinous borderline tumor: A retrospective analysis.
    Hada T; Miyamoto M; Ishibashi H; Matsuura H; Sakamoto T; Kakimoto S; Iwahashi H; Suzuki R; Sato K; Tsuda H; Takano M
    Medicine (Baltimore); 2021 Aug; 100(32):e26895. PubMed ID: 34397915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
    Simons M; Simmer F; Bulten J; Ligtenberg MJ; Hollema H; van Vliet S; de Voer RM; Kamping EJ; van Essen DF; Ylstra B; Schwartz LE; Wang Y; Massuger LF; Nagtegaal ID; Kurman RJ
    Mod Pathol; 2020 Apr; 33(4):722-733. PubMed ID: 31695154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
    Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt KA; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; ; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim BG; Kim JW; Kim JH; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park SY; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; ; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ
    Clin Cancer Res; 2022 Dec; 28(24):5383-5395. PubMed ID: 36222710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.